{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients with lung nodules received OTL38 (0.025mg/kg) preoperatively."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients with lung nodules received OTL38 (0.025mg/kg) preoperatively."
      },
      "Objective": {
        "score": 1,
        "evidence": "The primary goal was to determine if OTL38 improved surgeons\u2019 ability to identify hard-to-find nodules, occult cancers, and positive margins."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Efficacy was evaluated by occurrence of clinically significant events (CSE), occurrences that caused the surgeon to modify the operation or up-stage the patient\u2019s cancer."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 110 patients recruited; 92 were eligible for analysis."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 110 patients recruited; 92 were eligible for analysis."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "IMI found 24 additional nodules, 9 (10%) of which were cancers that had not been known preoperatively."
      },
      "Harms": {
        "score": 1,
        "evidence": "There were no serious adverse events."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "CLINICALTRIALS.GOV: NCT02872701"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}